Abstract：【Objective】To investigate the serum levels of galectin-3 and Apelin-12 in patients with hypertensive heart disease (HHD) and its clinical significance.【Methods】From October 2019 to October 2021, 160 patients with simple hypertension were selected as the hypertension group, and 137 patients with HHD were selected as HHD group. The left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left atrial diameter (LAD), left ventricular ejection fraction (LVEF), mitral valvular early diastolic peak velocity (E peak) and mitral valvular end diastolic peak velocity (A peak) were measured, and the E/A was calculated. The enzyme linked immunosorbent assay (ELISA) was used to detect serum levels of galectin-3 and Apelin-12, Pearson test was used to analyze the correlation between serum galectin-3 and Apelin-12 levels and cardiac color Doppler ultrasound parameters in patients with HHD; and receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of serum galectin-3 and Apelin-12 levels in HHD;Multivariate logistic regression model was used to analyze the risk factors of HHD in patients with hypertension.【Results】The systolic blood pressure(SBP), diastolic blood pressure(DBP), LVESD, LVEDD, IVST, LVPWT, LAD and serum galectin-3 level in HHD group were significantly higher than those in hypertension group (P<0.05), and the course of hypertension in HHD group was significantly longer than that in hypertension group (P<0.05). While LVEF, E/A and serum Apelin-12 level in HHD group were significantly lower than those in hypertension group (P<0.05). Pearson analysis showed that serum galectin-3 level was positively correlated with LVESD, LVEDD and LAD (P<0.05), and negatively correlated with LVEF and E/A (P<0.05); Apelin-12 level was negatively correlated with LVESD, LVEDD and LAD (P<0.05), and positively correlated with LVEF and E/A (P<0.05). The cutoff value of galectin-3 was 7.55 ng/mL, and the sensitivity and specificity were 67.20% and 82.50%, respectively, the cutoff value of Apelin-12 was 305.34 ng/L, the sensitivity and specificity were 73.70% and 71.90%, respectively, the sensitivity and specificity of galectin-3 and Apelin-12 combined diagnosis were 76.60% and 80.60% respectively. The course of hypertension and serum levels of galectin-3 and Apelin-12 were independent risk factors for HHD in patients with hypertension (P<0.05).【Conclusion】Galectin-3 is highly expressed in HHD patients, and the expression of Apelin-12 is lowly expressed. They are closely related to the structure and function of left ventricle.
倪烨, 钱一君, 张越月, 赵娅. 高血压性心脏病患者血清galectin-3、Apelin-12水平变化及其临床意义[J]. 医学临床研究, 2024, 41(11): 1699-1702.
NI Ye, QIAN Yijun, ZHANG Yueyue, et al. Expression and Clinical Significance of Galectin-3 and Apelin-12 in Serum of Patients with Hypertensive Heart Disease. JOURNAL OF CLINICAL RESEARCH, 2024, 41(11): 1699-1702.
[1] 何杰, 戴亨华, 杜令, 等. 血清PTX3和Gal-3在高血压合并冠状动脉粥样硬化性心脏病患者中的水平变化及其临床意义[J].国际检验医学杂志, 2020, 41(5):536-539. [2] PAN J A, MICHAËLSSON E, SHAW P W, et al. Extracellular volume by cardiac magnetic resonance is associated with biomarkers of inflammation in hypertensive heart disease[J].J Hypertens,2019, 37(1):65-72. [3] 周笔峰, 符妹垂, 邹婧, 等. 彩色多普勒超声诊断老年高血压性心脏病的价值[J].中国老年学杂志, 2020, 40(9):1805. [4] SUTHAHAR N, MEIJERS W C, SILLJÉ H H W, et al. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update[J].Theranostics,2018, 8(3):593-609. [5] 阿斯艳木·阿不都欧甫, 商鲁翔, 周贤惠, 等. Apelin/APJ系统与心血管疾病的研究进展[J].中国心脏起搏与心电生理杂志, 2019, 33(2):69-72. [6] 黄立华, 侯秀伟, 李伟. 重组人脑钠肽联合心脉隆注射液对心脏瓣膜置换术患者血清Apelin-12、D-二聚体及心功能的影响研究[J].河北医学, 2018, 24(8):1249-1254. [7] 《中国高血压基层管理指南》修订委员会. 中国高血压基层管理指南(2014年修订版)[J].中华高血压杂志,2015,23(1):24-43. [8] 党爱民, 陈炳伟. 2013欧洲高血压学会/欧洲心脏病学会高血压管理指南更新要点解读[J].中国循环杂志, 2013, 28(6):401-403. [9] DONG T W, LI H B, WANG S, et al. Efficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction[J].Exp Ther Med,2020,19(1):147-152. [10] CLEMENTY N, GARCIA B, ANDRÉ C, et al. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure[J].PLoS One,2018, 13(8):e0201517. [11] 孙宏超, 金凤表, 侯维娜, 等. 血清Galectin-3、PTX-3与扩张型心肌病心力衰竭临床指标的相关性[J].中国老年学杂志,2020,40(5):912-916. [12] 许卓帆, 郑韶欣, 叶贤区, 等. 慢性心力衰竭患者血清sST2、Galectin-3水平变化及临床意义[J].中国循证心血管医学杂志, 2020, 12(1):47-49. [13] KOVAL S, IUSHKO K, STARCHENKO T. Relations of Apelin with cardiac remodeling in patients with hypertension and type 2 diabetes[J].Folia Med (Plovdiv),2018, 60(1):117-123. [14] KUBA K, SATO T, IMAI Y, et al. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology[J].Peptides,2019,111(1):62-70. [15] WANG Y Z, FAN J, ZHONG B, et al. Apelin: A novel prognostic predictor for atrial fibrillation recurrence after pulmonary vein isolation[J].Medicine(Baltimore),2018, 97(39):e12580.
2024, Vol. 41 
